Spectral Diagnostics (Toronto, ON)
TSX : SDI
CMDF Investment: $4,850,000.00
CMDF II Investment: $500,000.00
Focus: Cardiovascular Diseases & Blood Products   Infectious Dieases  
www.spectraldiagnostics.com

Spectral Diagnostics Inc. remains dedicated to the research; development and commercialization of innovative rapid diagnostics. Our Cardiac STATus® line of products is sold worldwide as markers for rapid identification of a heart attack in patients. The Endotoxin Activity Assay is the first approved assay for rapid read as assessment for developing severe sepsis in the ICU. Our pipeline includes new assays for point-of-care diagnosis. Spectral is a Canadian publicly traded company incorporated in 1991 with operations in Canada; the United States and Europe. Spectral's products are available worldwide.